Aktis Oncology, Inc. 8-K

What Happened
Aktis Oncology, Inc. (filed 8-K on April 16, 2026) announced that on April 15, 2026 it appointed Glenn Gormley, MD, PhD as a Class I director, effective immediately. Dr. Gormley will serve until the 2027 Annual Meeting. He was also named Co‑Chair of a newly created Science and Technology Committee alongside director Ken Herrmann, MD, PhD. Separately, directors Helen S. Kim and Oleg Nodelman notified the company they will resign from the board and all committees effective May 20, 2026; their resignations are not due to any disagreement with the company.

Key Details

• Appointment effective April 15, 2026; Class I term expires at the 2027 Annual Meeting.
• Dr. Gormley, age 72, previously held senior R&D and executive roles at Daiichi Sankyo, Novartis, AstraZeneca and served as CEO of Gemin X.
• Director compensation per the company policy: $45,000/year for board service plus $15,000/year for Co‑Chair role (both prorated).
• Equity grant: option to purchase 37,866 shares under the 2026 Equity Incentive Plan, exercise price = Nasdaq closing price on April 15, 2026; vests in equal annual installments over three years, subject to continued service.
• Company entered into its standard indemnification agreement with Dr. Gormley and reported no related‑party transactions.

Why It Matters
These are governance-level changes that directly affect who oversees Aktis’s scientific and clinical strategy. Adding a seasoned pharmaceutical R&D leader like Dr. Gormley may influence the company’s development oversight and committee focus. The disclosed cash and equity awards follow the company’s non-employee director policy and represent typical board compensation; investors should note the share option grant and the timing of the upcoming board departures (effective May 20, 2026) when assessing near-term governance and potential proxy disclosures ahead of the 2027 Annual Meeting.